{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T15:09:58Z","timestamp":1789657798973,"version":"4.0.1"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:00:00Z","timestamp":1789603200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"DOI":"10.1007\/s40199-026-00636-8","type":"journal-article","created":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:55:29Z","timestamp":1789656929000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prasugrel in the management of acute coronary syndromes: a systematic review"],"prefix":"10.1007","volume":"34","author":[{"given":"Canan","family":"Akman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asli Bahar","family":"Ucar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Unaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gul","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Busra","family":"Erdem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinar","family":"Vargun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sennaz","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilgen","family":"Ozkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgur","family":"Karcioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,17]]},"reference":[{"issue":"5","key":"636_CR1","doi-asserted-by":"publisher","first-page":"568","DOI":"10.21037\/cdt.2018.07.01","volume":"8","author":"M Hamilos","year":"2018","unstructured":"Hamilos M, Petousis S, Parthenakis F. Interaction between platelets and endothelium: From pathophysiology to new therapeutic options. Cardiovasc Diagn Ther. 2018;8(5):568\u201380. https:\/\/doi.org\/10.21037\/cdt.2018.07.01.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"9678","key":"636_CR2","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(09)60503-1","volume":"373","author":"Antithrombotic Trialists Collaboration","year":"2009","unstructured":"Antithrombotic Trialists Collaboration. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis. Lancet. 2009;373(9678):1849\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(09)60503-1.","journal-title":"Lancet"},{"issue":"20","key":"636_CR3","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","volume":"357","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001\u201315. https:\/\/doi.org\/10.1056\/NEJMoa0706482.","journal-title":"N Engl J Med"},{"issue":"11","key":"636_CR4","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1056\/NEJMoa0904327","volume":"361","author":"L Wallentin","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045\u201357. https:\/\/doi.org\/10.1056\/NEJMoa0904327.","journal-title":"N Engl J Med"},{"issue":"10","key":"636_CR5","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1161\/01.CIR.0000140675.85342.1B","volume":"110","author":"KA Fox","year":"2004","unstructured":"Fox KA, Mehta SR, Peters R, et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for NSTE-ACS: the CURE trial. Circulation. 2004;110(10):1202\u20138. https:\/\/doi.org\/10.1161\/01.CIR.0000140675.85342.1B.","journal-title":"Circulation"},{"issue":"9281","key":"636_CR6","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/S0140-6736(01)05701-4","volume":"358","author":"SR Mehta","year":"2001","unstructured":"Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing PCI: the PCI-CURE study. Lancet. 2001;358(9281):527\u201333. https:\/\/doi.org\/10.1016\/S0140-6736(01)05701-4.","journal-title":"Lancet"},{"issue":"19","key":"636_CR7","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1001\/jama.288.19.2411","volume":"288","author":"SR Steinhubl","year":"2002","unstructured":"Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: the CREDO trial. JAMA. 2002;288(19):2411\u201320. https:\/\/doi.org\/10.1001\/jama.288.19.2411.","journal-title":"JAMA"},{"issue":"20","key":"636_CR8","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","volume":"136","author":"DJ Angiolillo","year":"2017","unstructured":"Angiolillo DJ, Rollini F, Storey RF, et al. International expert consensus on switching platelet P2Y12 receptor-inhibiting therapies. Circulation. 2017;136(20):1955\u201375. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.031164.","journal-title":"Circulation"},{"issue":"9","key":"636_CR9","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1592\/phco.29.9.1089","volume":"29","author":"PP Dobesh","year":"2009","unstructured":"Dobesh PP. Pharmacokinetics and pharmacodynamics of prasugrel, a thienopyridine P2Y12 inhibitor. Pharmacotherapy. 2009;29(9):1089\u2013102. https:\/\/doi.org\/10.1592\/phco.29.9.1089.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"636_CR10","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1161\/CIRCULATIONAHA.109.921502","volume":"122","author":"SD Wiviott","year":"2010","unstructured":"Wiviott SD, Antman EM, Braunwald E, Prasugrel. Circulation. 2010;122(4):394\u2013403. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.921502.","journal-title":"Circulation"},{"issue":"6","key":"636_CR11","doi-asserted-by":"publisher","first-page":"436","DOI":"10.7326\/M20-0116","volume":"173","author":"M Menichelli","year":"2020","unstructured":"Menichelli M, Neumann FJ, Ndrepepa G, et al. Age- and weight-adapted dose of prasugrel versus standard dose of ticagrelor in patients with acute coronary syndromes. Ann Intern Med. 2020;173(6):436\u201344. https:\/\/doi.org\/10.7326\/M20-0116.","journal-title":"Ann Intern Med"},{"issue":"16","key":"636_CR12","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1161\/CIRCULATIONAHA.108.791061","volume":"118","author":"SD Wiviott","year":"2008","unstructured":"Wiviott SD, Braunwald E, Angiolillo DJ, et al. Greater clinical benefit of prasugrel in patients with diabetes mellitus in TRITON-TIMI 38. Circulation. 2008;118(16):1626\u201336. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.108.791061.","journal-title":"Circulation"},{"issue":"16","key":"636_CR13","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","volume":"381","author":"S Schupke","year":"2019","unstructured":"Schupke S, Neumann FJ, Menichelli M, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes. N Engl J Med. 2019;381(16):1524\u201334. https:\/\/doi.org\/10.1056\/NEJMoa1908973.","journal-title":"N Engl J Med"},{"key":"636_CR14","doi-asserted-by":"publisher","unstructured":"Angiolillo DJ, Capranzano P. Pharmacology of emerging novel platelet inhibitors. Am Heart J. 2008;156(2 Suppl). https:\/\/doi.org\/10.1016\/j.ahj.2008.06.004. S10-15.","DOI":"10.1016\/j.ahj.2008.06.004"},{"issue":"16","key":"636_CR15","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1001\/jama.2010.1543","volume":"304","author":"JL Mega","year":"2010","unstructured":"Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA. 2010;304(16):1821\u201330. https:\/\/doi.org\/10.1001\/jama.2010.1543.","journal-title":"JAMA"},{"issue":"19","key":"636_CR16","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1161\/CIRCULATIONAHA.109.851949","volume":"119","author":"JL Mega","year":"2009","unstructured":"Mega JL, Close SL, Wiviott SD, et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel. Circulation. 2009;119(19):2553\u201360. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.851949.","journal-title":"Circulation"},{"issue":"1","key":"636_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/cpt.2450","volume":"111","author":"LH Cavallari","year":"2022","unstructured":"Cavallari LH, Lee CR, Beitelshees AL, et al. Pragmatic implementation of pharmacogenomics to guide P2Y12 inhibitor prescribing. Clin Pharmacol Ther. 2022;111(1):54\u201363. https:\/\/doi.org\/10.1002\/cpt.2450.","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"636_CR18","doi-asserted-by":"publisher","first-page":"e047768","DOI":"10.1161\/JAHA.125.047768","volume":"15","author":"LH Cavallari","year":"2026","unstructured":"Cavallari LH, Lee CR, Beitelshees AL, et al. 2025 acute coronary syndrome guideline: missing the boat on CYP2C19 genotyping. J Am Heart Assoc. 2026;15(10):e047768. https:\/\/doi.org\/10.1161\/JAHA.125.047768.","journal-title":"J Am Heart Assoc"},{"issue":"9694","key":"636_CR19","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","volume":"374","author":"ML O\u2019Donoghue","year":"2009","unstructured":"O\u2019Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor. Lancet. 2009;374(9694):989\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(09)61525-7.","journal-title":"Lancet"},{"issue":"20","key":"636_CR20","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1007964","volume":"363","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without omeprazole in coronary artery disease (COGENT). N Engl J Med. 2010;363(20):1909\u201317. https:\/\/doi.org\/10.1056\/NEJMoa1007964.","journal-title":"N Engl J Med"},{"issue":"25","key":"636_CR21","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1161\/CIRCULATIONAHA.107.740324","volume":"116","author":"SD Wiviott","year":"2007","unstructured":"Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the PRINCIPLE-TIMI 44 trial. Circulation. 2007;116(25):2923\u201332. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.740324.","journal-title":"Circulation"},{"key":"636_CR22","doi-asserted-by":"publisher","first-page":"905607","DOI":"10.3389\/fcvm.2022.905607","volume":"9","author":"L Dai","year":"2022","unstructured":"Dai L, Xu J, Jiang Y, Chen K. Impact of prasugrel and ticagrelor on platelet reactivity in patients with acute coronary syndrome: a meta-analysis. Front Cardiovasc Med. 2022;9:905607. https:\/\/doi.org\/10.3389\/fcvm.2022.905607.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"636_CR23","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1186\/s12872-020-01603-0","volume":"20","author":"M Wen","year":"2020","unstructured":"Wen M, Li Y, Qu X, et al. Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis. BMC Cardiovasc Disord. 2020;20(1):446. https:\/\/doi.org\/10.1186\/s12872-020-01603-0.","journal-title":"BMC Cardiovasc Disord"},{"issue":"25","key":"636_CR24","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1161\/CIRCULATIONAHA.109.912550","volume":"120","author":"PA Gurbel","year":"2009","unstructured":"Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel: the ONSET\/OFFSET study. Circulation. 2009;120(25):2577\u201385. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.912550.","journal-title":"Circulation"},{"issue":"3","key":"636_CR25","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/jth.13251","volume":"14","author":"D Alexopoulos","year":"2016","unstructured":"Alexopoulos D, Bhatt DL, Lekkos D, et al. Platelet inhibitory effects of prasugrel versus ticagrelor in STEMI patients with bivalirudin anticoagulation. J Thromb Haemost. 2016;14(3):589\u201396. https:\/\/doi.org\/10.1111\/jth.13251.","journal-title":"J Thromb Haemost"},{"issue":"6","key":"636_CR26","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1177\/2048872617748052","volume":"7","author":"A Sciahbasi","year":"2018","unstructured":"Sciahbasi A, Madonna M, De Vita M, et al. Comparison of prasugrel and ticagrelor antiplatelet effects in patients with ACS: a prospective, randomized, crossover study. Eur Heart J Acute Cardiovasc Care. 2018;7(6):522\u20138. https:\/\/doi.org\/10.1177\/2048872617748052.","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"6","key":"636_CR27","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.ahj.2014.03.011","volume":"167","author":"G Parodi","year":"2014","unstructured":"Parodi G, Bellandi B, Valenti R, et al. Comparison of double ticagrelor loading dose with standard prasugrel loading dose in STEMI patients. Am Heart J. 2014;167(6):909\u201314. https:\/\/doi.org\/10.1016\/j.ahj.2014.03.011.","journal-title":"Am Heart J"},{"issue":"15","key":"636_CR28","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","volume":"61","author":"G Parodi","year":"2013","unstructured":"Parodi G, Valenti R, Bellandi B, et al. Comparison of prasugrel and ticagrelor loading doses in STEMI patients: RAPID primary PCI study. J Am Coll Cardiol. 2013;61(15):1601\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2013.01.024.","journal-title":"J Am Coll Cardiol"},{"key":"636_CR29","doi-asserted-by":"publisher","first-page":"107613","DOI":"10.1016\/j.pharmthera.2020.107613","volume":"215","author":"K Ibrahim","year":"2020","unstructured":"Ibrahim K, Christopoulos C, Joury A, et al. High on-treatment platelet reactivity: key concepts, clinical implications and measurement. Pharmacol Ther. 2020;215:107613. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107613.","journal-title":"Pharmacol Ther"},{"issue":"26","key":"636_CR30","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1093\/eurheartj\/ehp247","volume":"30","author":"T Cuisset","year":"2009","unstructured":"Cuisset T, Cayla G, Frere C, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis: results of the ADRIE study. Eur Heart J. 2009;30(26):3361\u20139. https:\/\/doi.org\/10.1093\/eurheartj\/ehp247.","journal-title":"Eur Heart J"},{"issue":"1","key":"636_CR31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1161\/CIRCINTERVENTIONS.111.965749","volume":"5","author":"JL Ferreiro","year":"2012","unstructured":"Ferreiro JL, Angiolillo DJ. Platelet function testing in patients with coronary artery disease. Circ Cardiovasc Interv. 2012;5(1):119\u201329. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.111.965749.","journal-title":"Circ Cardiovasc Interv"},{"issue":"4","key":"636_CR32","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.ahj.2009.01.003","volume":"157","author":"S James","year":"2009","unstructured":"James S, Akerblom A, Cannon CP, et al. Comparison of ticagrelor with clopidogrel in patients with ACS: rationale, design, and baseline characteristics of the PLATO trial. Am Heart J. 2009;157(4):599\u2013605. https:\/\/doi.org\/10.1016\/j.ahj.2009.01.003.","journal-title":"Am Heart J"},{"issue":"9621","key":"636_CR33","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(08)60422-5","volume":"371","author":"SD Wiviott","year":"2008","unstructured":"Wiviott SD, Braunwald E, McCabe CH, et al. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with ACS treated with PCI in TRITON-TIMI 38. Lancet. 2008;371(9621):1353\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(08)60422-5.","journal-title":"Lancet"},{"issue":"5","key":"636_CR34","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.jacc.2012.04.016","volume":"60","author":"PK Smith","year":"2012","unstructured":"Smith PK, Goodnough LT, Levy JH, et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 CABG cohort. J Am Coll Cardiol. 2012;60(5):388\u201396. https:\/\/doi.org\/10.1016\/j.jacc.2012.04.016.","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"636_CR35","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nrcardio.2011.106","volume":"8","author":"S Savonitto","year":"2011","unstructured":"Savonitto S, Morici N, De Servi S. Treatment of acute coronary syndromes in the elderly and in patients with comorbidities. Nat Rev Cardiol. 2011;8(10):609\u201320. https:\/\/doi.org\/10.1038\/nrcardio.2011.106.","journal-title":"Nat Rev Cardiol"},{"issue":"14","key":"636_CR36","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1056\/NEJMoa1205512","volume":"367","author":"MT Roe","year":"2012","unstructured":"Roe MT, Armstrong PW, Fox KA, et al. Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med. 2012;367(14):1297\u2013309. https:\/\/doi.org\/10.1056\/NEJMoa1205512.","journal-title":"N Engl J Med"},{"issue":"47","key":"636_CR37","doi-asserted-by":"publisher","first-page":"3302","DOI":"10.1093\/eurheartj\/ehu425","volume":"35","author":"G Montalescot","year":"2014","unstructured":"Montalescot G, Collet JP, Betriu A, et al. Long-term follow-up after low-dose prasugrel in medically managed ACS patients: a subanalysis from TRILOGY ACS. Eur Heart J. 2014;35(47):3302\u20138. https:\/\/doi.org\/10.1093\/eurheartj\/ehu425.","journal-title":"Eur Heart J"},{"issue":"21","key":"636_CR38","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1016\/j.jacc.2020.09.558","volume":"76","author":"G Ndrepepa","year":"2020","unstructured":"Ndrepepa G, Schupke S, Behnes M, et al. Ticagrelor or prasugrel in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Cardiol. 2020;76(21):2436\u201346. https:\/\/doi.org\/10.1016\/j.jacc.2020.09.558.","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"636_CR39","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s00392-022-02040-z","volume":"112","author":"M Behnes","year":"2023","unstructured":"Behnes M, Lahu S, Ndrepepa G, et al. Ticagrelor or prasugrel in patients with ACS with off-hour versus on-hour presentation: a subgroup analysis of ISAR-REACT 5. Clin Res Cardiol. 2023;112(4):468\u201379. https:\/\/doi.org\/10.1007\/s00392-022-02040-z.","journal-title":"Clin Res Cardiol"},{"issue":"4","key":"636_CR40","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/ehjcvp\/pvaa054","volume":"7","author":"G Ndrepepa","year":"2021","unstructured":"Ndrepepa G, Cassese S, Xhepa E, et al. Sex-related differences in outcomes with prasugrel versus ticagrelor in patients with ACS: subgroup analysis of ISAR-REACT 5. Eur Heart J Cardiovasc Pharmacother. 2021;7(4):316\u201325. https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa054.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"21","key":"636_CR41","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1161\/CIRCULATIONAHA.116.024823","volume":"134","author":"Z Motovska","year":"2016","unstructured":"Motovska Z, Hlinomaz O, Miklik R, et al. Prasugrel versus ticagrelor in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: multicenter randomized PRAGUE-18 study. Circulation. 2016;134(21):1603\u201312. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.024823.","journal-title":"Circulation"},{"issue":"4","key":"636_CR42","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jacc.2017.10.090","volume":"71","author":"Z Motovska","year":"2018","unstructured":"Motovska Z, Hlinomaz O, Miklik R, et al. Prasugrel versus ticagrelor in STEMI: PRAGUE-18 one-year outcomes. J Am Coll Cardiol. 2018;71(4):371\u201381. https:\/\/doi.org\/10.1016\/j.jacc.2017.10.090.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"636_CR43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jcin.2017.09.003","volume":"11","author":"Z Motovska","year":"2018","unstructured":"Motovska Z, Hlinomaz O, Kala P, et al. 1-year outcomes of patients undergoing primary angioplasty for myocardial infarction treated with prasugrel versus ticagrelor: PRAGUE-18 study. JACC Cardiovasc Interv. 2018;11(1):107\u20138. https:\/\/doi.org\/10.1016\/j.jcin.2017.09.003.","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"636_CR44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1093\/eurheartj\/eht375","volume":"35","author":"D Aradi","year":"2014","unstructured":"Aradi D, Storey RF, Komocsi A, et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. Eur Heart J. 2014;35(4):209\u201315. https:\/\/doi.org\/10.1093\/eurheartj\/eht375.","journal-title":"Eur Heart J"},{"issue":"1","key":"636_CR45","doi-asserted-by":"publisher","first-page":"e13304","DOI":"10.1111\/eci.13304","volume":"51","author":"GM Gager","year":"2021","unstructured":"Gager GM, Jilma B, Winter MP, et al. Ticagrelor and prasugrel are independent predictors of improved long-term survival in ACS patients. Eur J Clin Invest. 2021;51(1):e13304. https:\/\/doi.org\/10.1111\/eci.13304.","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"636_CR46","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40360-017-0189-7","volume":"18","author":"PK Bundhun","year":"2017","unstructured":"Bundhun PK, Shi JX, Huang F. Head to head comparison of prasugrel versus ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis of randomized trials. BMC Pharmacol Toxicol. 2017;18(1):65. https:\/\/doi.org\/10.1186\/s40360-017-0189-7.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"636_CR47","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40256-019-00337-5","volume":"20","author":"A Greco","year":"2020","unstructured":"Greco A, Laudani C, Spagnolo M, et al. Prasugrel vs ticagrelor for DAPT in patients with ACS undergoing PCI: a systematic review and meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs. 2020;20(4):353\u201367. https:\/\/doi.org\/10.1007\/s40256-019-00337-5.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"3","key":"636_CR48","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10557-020-07056-z","volume":"21","author":"A Mentias","year":"2021","unstructured":"Mentias A, Patel K, Patel H, et al. Ticagrelor versus prasugrel in patients with acute coronary syndrome: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2021;21(3):561\u201374. https:\/\/doi.org\/10.1007\/s10557-020-07056-z.","journal-title":"Am J Cardiovasc Drugs"},{"issue":"9","key":"636_CR49","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.amjmed.2023.04.022","volume":"136","author":"S Farhan","year":"2023","unstructured":"Farhan S, Vogel B, Mehran R, et al. Ticagrelor versus prasugrel in patients with acute coronary syndrome: a systematic review and meta-analysis. Am J Med. 2023;136(9):858\u201365. https:\/\/doi.org\/10.1016\/j.amjmed.2023.04.022.","journal-title":"Am J Med"},{"issue":"1","key":"636_CR50","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1186\/s12872-026-05781-1","volume":"26","author":"SA Mirhosseini","year":"2026","unstructured":"Mirhosseini SA, Mousavi A, Dastjerdi P, et al. The efficacy and safety of ticagrelor and prasugrel versus clopidogrel in post-PCI DAPT in chronic coronary syndrome: systematic review and meta-analysis. BMC Cardiovasc Disord. 2026;26(1):392. https:\/\/doi.org\/10.1186\/s12872-026-05781-1.","journal-title":"BMC Cardiovasc Disord"},{"key":"636_CR51","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1186\/s12872-026-05880-z","volume":"26","author":"Y Xing","year":"2026","unstructured":"Xing Y, Bai C, Chen S, et al. Antiplatelet therapy in acute coronary syndrome: a systematic critical appraisal of current guidelines. BMC Cardiovasc Disord. 2026;26:458. https:\/\/doi.org\/10.1186\/s12872-026-05880-z.","journal-title":"BMC Cardiovasc Disord"},{"issue":"10","key":"636_CR53","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.jacc.2016.03.513","volume":"68","author":"GN Levine","year":"2016","unstructured":"Levine GN, Bates ER, Bittl JA, et al. 2016 ACC\/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Am Coll Cardiol. 2016;68(10):1082\u2013115. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.513.","journal-title":"J Am Coll Cardiol"},{"issue":"19","key":"636_CR54","doi-asserted-by":"publisher","first-page":"e025499","DOI":"10.1161\/JAHA.122.025499","volume":"11","author":"M Rashid","year":"2022","unstructured":"Rashid M, Locker T, More RS, et al. Dual antiplatelet therapy in patients aged 75 years and older with coronary artery disease: a meta-analysis and systematic review. J Am Heart Assoc. 2022;11(19):e025499. https:\/\/doi.org\/10.1161\/JAHA.122.025499.","journal-title":"J Am Heart Assoc"},{"issue":"38","key":"636_CR55","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720\u2013826. https:\/\/doi.org\/10.1093\/eurheartj\/ehad191.","journal-title":"Eur Heart J"},{"issue":"11","key":"636_CR56","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jcin.2018.03.017","volume":"11","author":"RHM Furtado","year":"2018","unstructured":"Furtado RHM, Bhatt DL, McGuire DK, et al. Prasugrel in patients with type 2 diabetes and established cardiovascular disease: subanalysis of TRITON-TIMI 38. JACC Cardiovasc Interv. 2018;11(11):1107\u201316. https:\/\/doi.org\/10.1016\/j.jcin.2018.03.017.","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"636_CR57","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.jcin.2020.07.032","volume":"14","author":"G Ndrepepa","year":"2021","unstructured":"Ndrepepa G, Sibbing D, Schupke S, et al. Ticagrelor or prasugrel in patients with acute coronary syndromes and diabetes mellitus. JACC Cardiovasc Interv. 2021;14(4):409\u201320. https:\/\/doi.org\/10.1016\/j.jcin.2020.07.032.","journal-title":"JACC Cardiovasc Interv"},{"key":"636_CR58","doi-asserted-by":"publisher","unstructured":"Angiolillo DJ, Bates ER, Bass TA. Clinical profile of prasugrel, a novel thienopyridine. Am Heart J. 2008;156(2 Suppl). https:\/\/doi.org\/10.1016\/j.ahj.2008.06.005. S16-22.","DOI":"10.1016\/j.ahj.2008.06.005"},{"issue":"20","key":"636_CR59","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs215","volume":"33","author":"PG Steg","year":"2012","unstructured":"Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33(20):2569\u2013619. https:\/\/doi.org\/10.1093\/eurheartj\/ehs215.","journal-title":"Eur Heart J"},{"issue":"2","key":"636_CR60","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"B Ibanez","year":"2018","unstructured":"Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of AMI in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119\u201377. https:\/\/doi.org\/10.1093\/eurheartj\/ehx393.","journal-title":"Eur Heart J"},{"issue":"1","key":"636_CR61","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s12872-020-01403-6","volume":"20","author":"Z Wang","year":"2020","unstructured":"Wang Z, Zhou DY, Su Y, Si LY, Xu Q. Prasugrel or ticagrelor relative to clopidogrel in triple-antiplatelet treatment for STEMI undergoing PCI: a meta-analysis. BMC Cardiovasc Disord. 2020;20(1):120. https:\/\/doi.org\/10.1186\/s12872-020-01403-6.","journal-title":"BMC Cardiovasc Disord"},{"issue":"12","key":"636_CR62","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1056\/NEJMoa1706443","volume":"377","author":"D Erlinge","year":"2017","unstructured":"Erlinge D, Omerovic E, Frobert O, et al. Bivalirudin versus heparin monotherapy in myocardial infarction (VALIDATE-SWEDEHEART). N Engl J Med. 2017;377(12):1132\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1706443.","journal-title":"N Engl J Med"},{"issue":"3","key":"636_CR63","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"M Valgimigli","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease. Eur Heart J. 2018;39(3):213\u201360. https:\/\/doi.org\/10.1093\/eurheartj\/ehx419.","journal-title":"Eur Heart J"},{"issue":"31","key":"636_CR64","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1093\/eurheartj\/ehz372","volume":"40","author":"P Urban","year":"2019","unstructured":"Urban P, Mehran R, Colleran R, et al. Defining high bleeding risk in patients undergoing PCI: ARC-HBR consensus document. Eur Heart J. 2019;40(31):2632\u201353. https:\/\/doi.org\/10.1093\/eurheartj\/ehz372.","journal-title":"Eur Heart J"},{"issue":"3","key":"636_CR65","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1093\/ehjcvp\/pvab039","volume":"8","author":"D Steubl","year":"2022","unstructured":"Steubl D, Bucher J, Huebner M, et al. Renal function and outcomes with prasugrel versus ticagrelor in ACS: analysis from ISAR-REACT 5. Eur Heart J Cardiovasc Pharmacother. 2022;8(3):267\u201375. https:\/\/doi.org\/10.1093\/ehjcvp\/pvab039.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"11","key":"636_CR66","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.109.933796","volume":"122","author":"S James","year":"2010","unstructured":"James S, Budaj A, Aylward P, et al. Ticagrelor versus clopidogrel in ACS in relation to renal function: results from the PLATO trial. Circulation. 2010;122(11):1056\u201367. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.933796.","journal-title":"Circulation"},{"issue":"14","key":"636_CR67","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","volume":"42","author":"JP Collet","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289\u2013367. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa575.","journal-title":"Eur Heart J"},{"issue":"3","key":"636_CR68","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.cjca.2017.12.012","volume":"34","author":"SR Mehta","year":"2018","unstructured":"Mehta SR, Bainey KR, Cantor WJ, et al. 2018 Canadian Cardiovascular Society\/CAIC focused update on antiplatelet therapy. Can J Cardiol. 2018;34(3):214\u201333. https:\/\/doi.org\/10.1016\/j.cjca.2017.12.012.","journal-title":"Can J Cardiol"},{"issue":"20","key":"636_CR69","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/eurheartj\/ehv101","volume":"36","author":"M Valgimigli","year":"2015","unstructured":"Valgimigli M, Ariotti S, Costa F. Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus? Eur Heart J. 2015;36(20):1219\u201322. https:\/\/doi.org\/10.1093\/eurheartj\/ehv101.","journal-title":"Eur Heart J"},{"issue":"7","key":"636_CR70","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/nrd3771","volume":"11","author":"DL Bhatt","year":"2012","unstructured":"Bhatt DL, Topol EJ. Thrombosis, bleeding and balance: insights from contemporary antiplatelet strategies. Nat Rev Drug Discov. 2012;11(7):537\u20138. https:\/\/doi.org\/10.1038\/nrd3771.","journal-title":"Nat Rev Drug Discov"},{"issue":"10104","key":"636_CR71","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/S0140-6736(17)32155-4","volume":"390","author":"D Sibbing","year":"2017","unstructured":"Sibbing D, Aradi D, Jacobshagen C, et al. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS). Lancet. 2017;390(10104):1747\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(17)32155-4.","journal-title":"Lancet"},{"issue":"17","key":"636_CR72","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1907096","volume":"381","author":"DMF Claassens","year":"2019","unstructured":"Claassens DMF, Vos GJA, Bergmeijer TO, et al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI (POPular Genetics). N Engl J Med. 2019;381(17):1621\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1907096.","journal-title":"N Engl J Med"},{"issue":"10073","key":"636_CR73","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","volume":"389","author":"F Costa","year":"2017","unstructured":"Costa F, van Klaveren D, James S, et al. Derivation and validation of the PRECISE-DAPT score. Lancet. 2017;389(10073):1025\u201334. https:\/\/doi.org\/10.1016\/S0140-6736(17)30397-5.","journal-title":"Lancet"},{"issue":"15","key":"636_CR74","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1093\/eurheartj\/ehr204","volume":"32","author":"PG Steg","year":"2011","unstructured":"Steg PG, Huber K, Andreotti F, et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the ESC Working Group on Thrombosis. Eur Heart J. 2011;32(15):1854\u201364. https:\/\/doi.org\/10.1093\/eurheartj\/ehr204.","journal-title":"Eur Heart J"},{"issue":"9824","key":"636_CR75","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/S0140-6736(12)60324-9","volume":"379","author":"T Palmerini","year":"2012","unstructured":"Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379(9824):1393\u2013402. https:\/\/doi.org\/10.1016\/S0140-6736(12)60324-9.","journal-title":"Lancet"},{"issue":"5","key":"636_CR76","doi-asserted-by":"publisher","first-page":"e001362","DOI":"10.1161\/CIRCINTERVENTIONS.114.001362","volume":"8","author":"P Genereux","year":"2015","unstructured":"Genereux P, Rutledge DR, Palmerini T, et al. Stent thrombosis and dual antiplatelet therapy interruption with everolimus-eluting stents: insights from Xience V Trials. Circ Cardiovasc Interv. 2015;8(5):e001362. https:\/\/doi.org\/10.1161\/CIRCINTERVENTIONS.114.001362.","journal-title":"Circ Cardiovasc Interv"},{"issue":"16","key":"636_CR77","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation (RE-DUAL PCI). N Engl J Med. 2017;377(16):1513\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1708454.","journal-title":"N Engl J Med"},{"issue":"21","key":"636_CR78","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","volume":"381","author":"R Mehran","year":"2019","unstructured":"Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI (TWILIGHT). N Engl J Med. 2019;381(21):2032\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1908419.","journal-title":"N Engl J Med"},{"issue":"20","key":"636_CR79","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/j.jacc.2013.02.036","volume":"61","author":"N Sarafoff","year":"2013","unstructured":"Sarafoff N, Martischnig A, Weiler J, et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent and indication for oral anticoagulation. J Am Coll Cardiol. 2013;61(20):2060\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2013.02.036.","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"636_CR80","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14779072.2019.1635009","volume":"17","author":"D Alexopoulos","year":"2019","unstructured":"Alexopoulos D, Xanthopoulou I, Storey RF, et al. Prasugrel versus ticagrelor in patients with acute coronary syndrome: an expert perspective. Expert Rev Cardiovasc Ther. 2019;17(7):479\u201389. https:\/\/doi.org\/10.1080\/14779072.2019.1635009.","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"636_CR81","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"issue":"19","key":"636_CR82","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/j.jcin.2024.08.022","volume":"17","author":"M Galli","year":"2024","unstructured":"Galli M, Gragnano F, Berteotti M, et al. Antithrombotic therapy in high bleeding risk, part I: percutaneous cardiac interventions. JACC Cardiovasc Interv. 2024;17(19):2197\u2013215. https:\/\/doi.org\/10.1016\/j.jcin.2024.08.022.","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"636_CR83","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11883-026-01414-2","volume":"28","author":"A Mauriello","year":"2026","unstructured":"Mauriello A, De Falco A, Correra A, et al. Pharmacogenomics of atherosclerotic plaque: pathophysiological background and therapeutic perspectives. Curr Atheroscler Rep. 2026;28(1):53. https:\/\/doi.org\/10.1007\/s11883-026-01414-2.","journal-title":"Curr Atheroscler Rep"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00636-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-026-00636-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-026-00636-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:55:31Z","timestamp":1789656931000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-026-00636-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,17]]},"references-count":82,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["636"],"URL":"https:\/\/doi.org\/10.1007\/s40199-026-00636-8","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,17]]},"assertion":[{"value":"25 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No ethical approval is required for this review article.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have provided consent for publication.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":3,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"79"}}